KalVista Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
EKTERLY's launch has seen rapid uptake in the US, Germany, and Japan, with strong physician and patient satisfaction and over 20% market penetration. Formulary access is expanding, pediatric and short-term prophylaxis opportunities are advancing, and the company is well-funded to reach profitability.
-
EKTERLY's U.S. launch drove $49.1M in eight-month revenue, with rapid adoption and strong patient and physician satisfaction. Global expansion is underway, and EKTERLY is now a first-line therapy for adolescents, supporting long-term growth.
-
The conference highlighted the rapid adoption of a new oral on-demand HAE therapy, which is driving earlier and more frequent treatment of attacks, expanding market potential, and shifting patient and prescriber behavior. Growth is strong, with refill rates and sales exceeding expectations.
-
Ekterly's launch has exceeded expectations, driven by robust clinical data, strong physician and patient satisfaction, and effective support services. Revenue is increasingly driven by refills, with high-burden patients adopting at above-average rates. The company is focused on expanding indications and maintaining its first-mover advantage.
-
EKTERLY's launch drove $13.7M in sales with rapid adoption among high-burden HAE patients and strong refill rates. International expansion is progressing, and payer access is expected to broaden in 2026. The company is fully funded through profitability.
-
ECTERLEET's U.S. launch saw rapid adoption, generating $1.4M in first-quarter revenue and strong engagement from patients and prescribers. International regulatory progress and robust cash reserves support continued expansion and investment.
Fiscal Year 2025
-
EKTERLY's rapid adoption as the first oral HAE therapy has driven strong market penetration and high patient satisfaction, with severe disease patients leading early uptake. Commercial processes are streamlining, international launches are underway, and the product's safety and convenience are reinforcing its market position.
-
EKTERLY’s launch has seen rapid adoption, especially among high-attack-rate HAE patients, with strong revenue and positive feedback. Payer coverage is progressing, and international expansion is underway, focusing on Europe and Japan with a lean commercial model.
-
EKTERLY, an oral therapy for acute HAE attacks, launched in the U.S. after FDA approval and is expanding globally. Clinical data show rapid, early treatment and strong safety, with high physician and patient enthusiasm supporting a major commercial rollout.
-
FDA approved Ekterly, the first oral on-demand HAE treatment for patients 12+, offering rapid, safe, and effective relief with broad label flexibility. The launch is set for mid-July, with strong adoption expected and global expansion planned through 2026.
-
Sebetralstat is on track for imminent FDA approval, with broad label expectations and launches in Europe and Japan to follow. The commercial team is fully prepared, physician and patient engagement is high, and payer feedback supports favorable access and pricing. Market growth is anticipated as treatment rates rise and the company is financially well-positioned.
-
Sebetralstat is poised to become the first oral on-demand therapy for hereditary angioedema, addressing a long-standing gap in the market. Clinical data show robust efficacy, safety, and rapid treatment, with strong payer and physician support ahead of a June 17 approval decision.
-
Sebetralstat is nearing FDA approval with a clean review and robust clinical data, targeting a July U.S. launch and global expansion. Commercial and operational preparations are advanced, with strong market opportunity in both U.S. and ex-U.S. on-demand HAE segments.
-
Sebetralstat is set to become the first oral, on-demand HAE therapy, with robust clinical data supporting rapid, guideline-aligned treatment and strong adoption intent among patients and physicians. The company is prepared for a global launch, supported by experienced teams, favorable market dynamics, and financial strength.
-
Sebetralstat is advancing toward a June U.S. approval for on-demand HAE treatment, with robust clinical data and a global launch strategy. The product’s ease of use and strong efficacy are expected to increase treatment rates and address unmet needs, supported by a focused sales force and premium pricing.
-
Sebetralstat, an oral on-demand HAE therapy, is poised for FDA approval with strong clinical data across all attack types and high physician enthusiasm. Launch preparations include robust clinician outreach, patient awareness, and payer engagement, with expectations for rapid adoption and significant market expansion.
Fiscal Year 2024
-
Sebetralstat, an oral on-demand HAE therapy, is under FDA review with a June 2025 PDUFA date and global launches planned. Robust clinical data show rapid symptom relief, broad efficacy, and a strong safety profile, positioning it to disrupt the current injectable-dominated market.
-
Sebetralstat, an oral on-demand therapy for HAE, is progressing smoothly through global regulatory reviews, with a US PDUFA date in June 2025. The company is preparing for launch with a focused commercial strategy, targeting early adoption by poorly controlled prophylaxis users and aiming to capture a significant share of the $900M+ on-demand market.
-
Sebetralstat, an oral HAE therapy, showed rapid efficacy and strong safety in the largest, most inclusive HAE trial to date, with early treatment and high attack coverage. Plans are set for global launch, targeting both on-demand and breakthrough attack populations, with a lean commercial model and positive payer outlook.